Mark E. Schneiderhan, PharmD, BCPP

Associate Professor, Department of Pharmacy Practice and Pharmaceutical Sciences

Mark E. Schneiderhan

Contact Info

Office Phone 218-726-6010

Fax 218-726-7781

Office Address:
113 Life Science, Duluth

Mailing Address:
University of Minnesota
College of Pharmacy, Duluth
Department of Pharmacy Practice and Pharmaceutical Sciences
232 Life Science
1110 Kirby Drive
Duluth, MN 55812-3003

Administrative Assistant Name
Anna Foster

Administrative Phone

Administrative Email

Associate Professor, Department of Pharmacy Practice and Pharmaceutical Sciences

Comprehensive Medication Management (CMM) Provider

Residency, Psychiatric Pharmacotherapy, Western Missouri Mental Health Center, Kansas City, MO (1993)

Psychiatry Fellowship, Western Missouri Mental Health Center, Kansas City, MO (1994)

PharmD, University of Kentucky, College of Pharmacy (1992)

BS, Ferris State University, College of Pharmacy (1986)


Dr. Schneiderhan is a Board Certified Psychiatric Pharmacist (BCPP) and Associate Professor in the department of Pharmacy Practice and Pharmaceutical Sciences at the University of Minnesota. He provides Comprehensive Medication Management (CMM) at the Human Development Center, Duluth, Minnesota, a community mental health facility serving NE Minnesota and NW Wisconsin regions. Dr. Schneiderhan has practiced in psychiatry and academia since 1994. His clinical duties include: Assessment of psychiatric and substance use disorders, Medication prescribing under collaborative practice agreement, Pharmacogenetics/pharmacokinetics consultations, and Psychopharmacy consultative services to primary care providers. He provides education specializing in schizophrenia, mood disorders, anxiety disorders, behavioral dyscontrol, and substance use disorders for pharmacy students.


Management of symptoms of Schizophrenia, Major Depressive Disorders, Bipolar Disorders, Anxiety disorders, OCD and PTSD, Behavioral dyscontrol disorders, and Substance use disorders

Awards & Recognition

  • University of Minnesota Academy for Excellence in Clinical Practice 2020 Inductee - This award serves as the highest recognition of excellence in the practice or provision of clinical care by a full-time faculty member.

Professional Associations

College of Psychiatric and Neurologic Pharmacists (CPNP) www.cpnp.or

American College of Clinical Pharmacists (ACCP)

American Association of Colleges of Pharmacy (AACP)

Minnesota Pharmacist Association, Professional Affairs


Research Summary/Interests

Metabolic-risk among patients with serious mental illness and concurrent antipsychotic therapy

Research Funding Grants

Medica Foundation


Okoro ON, Bastianelli KM, Wen Y, Bilden E, Konowalchuk BK, Schneiderhan ME. Awareness of state legislation on naloxone accessibility associated with willingness to prescribe naloxone. Subst Abuse 2017;online;1-5.

Brown JT, Schneiderhan ME, Eum S, Bishop JR. “Serum clomipramine and desmethlyclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.” Pharmacogenomics 2017;18(7):

Schneiderhan ME, Eum S, Brown JT, Bishop JR. “Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report” BMC Psychiatry 2017;17:238:

Schneiderhan ME, Nelson, Leigh A., Bauer, S. “Assessment of Psychiatric Disorders.” In: DiPiro, Talbert, Yee, Matzke, Wells, Posey. eds. Pharmacotherapy: A Pathophysiological Approach, Tenth Edition. The McGraw-Hill Company, Inc. (eChapter62) 2017.

Schneiderhan ME, Shuster S, Davey CS. “12-month prospective randomized study of pharmacists utilizing point-of-care screenings for metabolic syndrome and related conditions in subjects prescribed antipsychotics.” Prim Care Companion CNS Disord 2014;16(5): (

Schneiderhan ME. Two Case Reports of Smoking Behavior Changes After Self-initiated E-cigarette Use and Tobacco Smoking Cessation. Ment Health Clin. 2012;2(6):26. Available at: Accessed March 7, 2013.

Batscha C, Schneiderhan ME, Kataria Y, Rosen C, Marvin R. "Treatment settings and metabolic monitoring for people experiencing first-episode psychosis." J Psychosoc Nur Ment Health Serv 2010;48(9):44-49.

Schneiderhan ME, Batscha C, Rosen C. “Assessment of a Point-of-Care Metabolic Risk Screening Program in Outpatients Receiving Antipsychotic Agents.” Pharmacotherapy 2009;29(8):975-987.

Schneiderhan ME, Marvin R. “Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain.” Am J Ther 2007;14:581–584.

Kaplan KJ, Schneiderhan ME, Harrow M, Omens R. “Autonomy, Gender, and Preference for Paternalistic or Informative Physicians: A Study of the Doctor-Patient Relation.” Ethics & Medicine 2002;18(1):49-60.

Kaplan KJ, Harrow M, Schneiderhan ME. “Suicide, Physician-Assisted Suicide and Euthanasia in Men versus Women around the world: The Degree of Physician Control.” Ethics & Medicine, 2002;18(1):33-48.

Bunker MT, Marken PA, Schneiderhan ME, Ruehter VL. “Attenuation of antipsychotic-induced hyperprolactinemia with clozapine.” J Child Adolesc Psychopharmacol 1997;7(1):65-69.

Littrell RA, Schneiderhan M, “The Neurobiology of Schizophrenia.” Pharmacotherapy 1996;16(6):143s-147s; Discussion 166s-168s

Schneiderhan ME, Gross AG, Marken PA; Ruehter VL, Schmidt SL. “Conversion from oral to i.m. fluphenazine is not a simple matter.” Am J Health Syst Pharm 1995 Dec 15:52(24):2826-7.

Schneiderhan ME, Marken PA. “An atypical course of neuroleptic malignant syndrome.” J Clin Pharmacol. 1994;34(4):325-334.

Schneiderhan ME. “Is vitamin E effective in the treatment of tardive dyskinesia?” Ann Pharmacother. 1993;27(3):311-312.



  • Psychiatry


Human Development Center

Board Certifications

Board Certified Psychiatric Pharmacist (BCPP)



Unfamiliarity with naloxone rules leads to low prescribing rates among MN providers